Pneumococcal polysaccharide–protein (CRM₁₉₇) conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule

References

• Mulholland K. Strategies for the control of pneumococcal diseases. Vaccine17(Suppl. 1), S79–S84 (1999).
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics106(2), 362–366 (2000).
   PubMed Web of Science ®Google Scholar
• Prevnar®, package insert. Wyeth Pharmaceuticals Inc., PA, USA.
   Google Scholar
• Black S, Shinefield H, Fireman B et al. Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J.19(3), 187–195 (2000).
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A et al. Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med.344(6), 403–409 (2001).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N. Engl. J. Med.348(18), 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Mason EO Jr, Wald ER et al. Decrease of invasive pneumococcal infections in children among 8 children’s hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics113(3), 443–449 (2004).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb. Mortal. Wkly Rep.54(36), 893–897 (2005).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction – eight states, 1998–2005. MMWR Morb. Mortal. Wkly Rep.57(6), 144–148 (2008).
   PubMedGoogle Scholar
• Poehling KA, Szilagyi PG, Grijalva CG et al. Reduction of frequent otitis media and pressure equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics119(4), 707–715 (2007).
   PubMed Web of Science ®Google Scholar
• Hsu HE, Shutt KA, Moore MR et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N. Engl. J. Med.360(3), 244–256 (2009).
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet369(9568), 1179–1186 (2007).
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Ling S et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J.21(9), 810–815 (2002).
   PubMed Web of Science ®Google Scholar
• Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001–2006. Euro. Surveill.13(7–9), 1–6 (2008).
   Google Scholar
• Aristegui J, Bernaola E, Pocheville I et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur. J. Clin. Microbiol. Infect. Dis.26(5), 303–310 (2007).
   PubMed Web of Science ®Google Scholar
• Barricarte A, Castilla J, Gil-Setas A et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case–control study. Clin. Infect. Dis.44(11), 1436–1441 (2007).
   PubMed Web of Science ®Google Scholar
• Lernout T, Sabbe M. Surveillance de maladies infectieuses pediatriques en Belgique. Rapport annuel 2007 [in French]. IPH/Epireports, Institut scientifique de Santé publique, Brussels, Belgium (2008).
   Google Scholar
• Harboe ZB, Valentiner-Branth P, Benfield TL et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine28(14), 2642–2647 (2010).
   PubMed Web of Science ®Google Scholar
• Durando P, Crovari P, Ansaldi F et al. Collaborative Group for Pneumococcal Vaccination in Liguria. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine27(25–26), 3459–3462 (2009).
   PubMed Web of Science ®Google Scholar
• De Wals P, Robin E, Fortin E, Thibeault R, Ouakki M, Douville-Fradet M. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr. Infect. Dis. J.27(11), 963–968 (2008).
   PubMed Web of Science ®Google Scholar
• Boulianne N, De Wals P, Deceuninck G et al. Impact du Programme D’Immunisation par le Vaccin Pneumococcique Conjugue Heptavalent (VPC-7), au Quebec, Canada. Institut National de Sante Publique du Quebec. Gouvernement du Québec, Québec, Canada (2007).
   Google Scholar
• Paulus S, David ST, Tang W et al. Incidence of invasive pneumococcal disease after introduction of the universal infant immunization program, British Columbia (2002–2005). Can. Commun. Dis. Rep.32(14), 157–164 (2006).
   PubMedGoogle Scholar
• World Health Organization. WHO Technical Report Series, number 927. World Health Organization, Geneva, Switzerland (2005).
   Google Scholar
• Feavers I, Knezevic I, Powell M, Griffiths E. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7–8 July 2008, Ottawa, Canada. Vaccine27(28), 3681–3688 (2009).
   PubMed Web of Science ®Google Scholar
• Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr. Infect. Dis. J.29(8), 1–7 (2010).
   PubMed Web of Science ®Google Scholar
• Russell FM, Balloch A, Tang MLK et al. Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine27(41), 5685–5691 (2009).
   PubMed Web of Science ®Google Scholar
• Russell FM, Carapetis JR, Burton RL et al. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine29(3), 535–544 (2010).
   PubMed Web of Science ®Google Scholar
• Russell FM, Licciardi PV, Balloch A et al. Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine28(18), 3086–3094 (2010).
   PubMed Web of Science ®Google Scholar
• Sigurdardottir ST, Davidsdottir K, Arason VA et al. Safety and immunogenicity of CRM197-conjugated pneumococcal–meningococcal C combination vaccine (9vPnC–MnCC) whether given in two or three primary doses. Vaccine26(33), 4178–4186 (2008).
   PubMed Web of Science ®Google Scholar
• Rennels MB, Edwards KM, Keyserling HL et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics101(4), 604–611 (1998).
   PubMed Web of Science ®Google Scholar
• Huebner RE, Mbelle N, Forrest B, Madore DV, Klugman KP. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr. Infect. Dis. J.21(11), 1004–1007 (2002).
   PubMed Web of Science ®Google Scholar
• Ekström N, Ahman H, Verho J et al. Finnish Otitis Media Study Group. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect. Immun.73(1), 369–377 (2005).
   PubMed Web of Science ®Google Scholar
• Esposito S, Pugni L, Bosis S et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine23(14), 1703–1708 (2005).
   PubMed Web of Science ®Google Scholar
• Käyhty H, Ahman H, Eriksson K, Sorberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr. Infect. Dis. J.24(2), 108–114 (2005).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Ashton L et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J.25(4), 312–319 (2006).
   PubMed Web of Science ®Google Scholar
• Rodenburg GD, van Gils EJM, Veenhoven RH et al. Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses. Vaccine28(5), 1391–1396 (2010).
   PubMed Web of Science ®Google Scholar
• Goldblatt G, Southern J, Ashton L et al. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr. Infect. Dis. J.29(4), 1–5 (2010).
   PubMed Web of Science ®Google Scholar
• van Gils EJM, Veenhoven RH, Hak E et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA302(2), 159–167 (2009).
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Salt P, Oh S, Marchant A, Beverley P, Pollard AJ. The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine. Immunology119(3), 328–337 (2006).
   PubMed Web of Science ®Google Scholar
• Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert. Rev. Vaccines5(6), 851–857 (2006).
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Miller E et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis.179(6), 1569–1572 (1999).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet364(9431), 365–367 (2004).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Pilishvili T, Farley MM et al. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet368(9546), 1495–1502 (2006).
   PubMed Web of Science ®Google Scholar
• Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr. Infect. Dis. J.29(6), 1–4 (2010).
   PubMed Web of Science ®Google Scholar
• Crisinel PA, Chevalier I, Rallu F et al. Invasive pneumococcal disease after implementation of a reduced three-dose pneumococcal conjugate vaccine program: a pediatric tertiary care center experience. Eur. J. Pediatr.169(11), 1311–1315 (2010).
   PubMed Web of Science ®Google Scholar
• De Wals PD, Carbon M, Sévin E, Deceuninck G, Ouakki M. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr. Infect. Dis. J.28(9), e271–e274 (2009).
   PubMedGoogle Scholar
• Kaye P, Slack M, George R, Ladhani S, Borrow R, Miller E. The impact of the introduction of Prevenar™ on pneumococcal disease in England and Wales. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8–12 June 2008.
   Google Scholar
• Kaye P, Malkani R, Martin S et al. Invasive pneumococcal disease (IPD) in England and Wales after 7-valent conjugate vaccine (PCV7): potential impact of 10- and 13-valent vaccines. Presented at: 27th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Brussels, Belgium, 9–13 June 2009.
   Google Scholar
• Vestrheim DF, Lovoll O, Aaberge IS et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine26(26), 3277–3281 (2008).
   PubMed Web of Science ®Google Scholar
• De Carvalho Gomes H, Muscat M, Monnet DL, Giesecke J, Lopalco PL. Use of 7-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001–2007. Euro. Surveill.14(12), 1–6 (2009).
   Google Scholar
• Vestrheim DF, Høiby EA, Bergsaker MR, Rønning K, Aaberge IS, Caugant DA. Indirect effect of conjugate pneumococcal vaccination in a 2 + 1 dose schedule. Vaccine28(10), 2214–2221 (2010).
   PubMed Web of Science ®Google Scholar
• Poehling KA, Talbot TR, Griffin MR et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA295(14), 1668–1674 (2006).
   PubMed Web of Science ®Google Scholar
• Lexau CA, Lynfield R, Danila R et al. Active bacterial core surveillance team. changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA294(16), 2043–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Poehling KA, Nuorti JP et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics118(3), 865–873 (2006).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Limited supply of pneumococcal conjugate vaccine: suspension of recommendation for fourth dose. MMWR Morb. Mortal. Wkly Rep.53(5), 108–109 (2004).
   Google Scholar
• Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Siber GR, Kohberger R. Serum serotype-specific pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J. Infect. Dis.192(3), 367–376 (2005).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Hussain M, Andrews N et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J. Infect. Dis.192(3), 387–393 (2005).
   PubMed Web of Science ®Google Scholar
• Jokinen JT, Ahman H, Kilpi TM, Makela PH, Kayhty MH. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J. Infect. Dis.190(3), 545–550 (2004).
   PubMed Web of Science ®Google Scholar
• Russell FM, Carapetis JR, Satzke C et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide booster. Clin. Vaccine. Immunol.17(12), 1970–1976 (2010).
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Abu-Abed J, Rosenblum H, Greenberg D. Nasopharyngeal pneumococcal carriage (NPC) in first year of life following administration of two or three doses of 7-valent CRM-conjugate vaccine (PCV7). Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007.
   Google Scholar
• Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized, controlled trial. Pediatr. Infect. Dis. J.29(8), 756–762 (2010).
   PubMed Web of Science ®Google Scholar
• Pelton SI, Weycker D, Klein JO, Strutton D, Ciuryla V, Oster G. 7-valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine28(6), 1575–1582 (2010).
   PubMed Web of Science ®Google Scholar
• Vestrheim DF, Høiby EA, Aaberge IS, Caugant DA. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin. Vaccine Immunol.17(3), 325–334 (2010).
   PubMed Web of Science ®Google Scholar
• Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J.22(1), 10–16 (2003).
   PubMed Web of Science ®Google Scholar
• Esposito S, Lizioli A, Lastrico A et al. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. Respir. Res.8, 12 (2007).
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2004–2005 season. Can. Commun. Dis. Rep.30, 1–32 (2004).
   PubMedGoogle Scholar
• Patrzalek M, Albrecht P, Sobczynski M. Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur. J. Clin. Microbiol. Infect. Dis.29(7), 787–792 (2010).
   PubMed Web of Science ®Google Scholar
• Ghaffar F, Barton T, Lozano J et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin. Infect. Dis.39(7), 930–938 (2004).
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Zamir O, Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr. Infect. Dis. J.22(6), 532–540 (2003).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. MMWR Morb. Mortal. Wkly Rep.53(8), 177–178 (2004).
   PubMedGoogle Scholar
• Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J. Infect. Dis.201(10), 1570–1579 (2010).
   PubMed Web of Science ®Google Scholar
• Väkeväinen M, Soininen AQ, Lucero M et al. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J. Pediatr.157(5), 778–783 (2010).
   PubMed Web of Science ®Google Scholar
• Wisloff T, Abrahamsen TG, Bergsaker MAR et al. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine24(29–30), 5690–5699 (2006).
   PubMed Web of Science ®Google Scholar
• Dobay O, Ungvári Á, Kardos S et al. Genotypic and phenotypic characterisation of invasive Streptococcus pneumoniae isolates from Hungary, and coverage of the conjugate vaccines. J. Clin. Pathol.63(12), 1116–1120 (2010).
   PubMed Web of Science ®Google Scholar
• Messina AF, Katz-Gaynor K, Barton T et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr. Infect. Dis. J.26(6), 461–467 (2007).
   PubMed Web of Science ®Google Scholar
• Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA297(16), 1784–1792 (2007).
   PubMed Web of Science ®Google Scholar
• Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr. Infect. Dis. J.25(3), 250–254 (2006).
   PubMed Web of Science ®Google Scholar
• Byington CL, Samore MH, Stoddard GJ et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin. Infect. Dis.41(1), 21–29 (2005).
   PubMed Web of Science ®Google Scholar
• Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-Area Streptococcus pneumoniae Research (CASPER) Study. Clin. Infect. Dis.49(6), 205–212 (2009).
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Lynfield R, Schaffner W et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med.354(14), 1455–1463 (2006).
   PubMed Web of Science ®Google Scholar
• Pelton SI, Huot H, Finkelstein JA et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J.26(6), 468–472 (2007).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA298(15), 1772–1778 (2007).
   PubMed Web of Science ®Google Scholar
• McEllistrem MC, Adams JM, Patel K et al. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin. Infect. Dis.40(12), 1738–1744 (2005).
   PubMed Web of Science ®Google Scholar
• Lagos R, Munoz A, San Martin O et al. Age- and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile, 1994–2007. J. Infect. Dis.198(12), 1809–1817 (2008).
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis.201(1), 32–41 (2010).
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Dagan R, Givon-Lavi N, Regev-Yochay G, Malley R, Lipsitch M. Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. J. Infect. Dis.197(11), 1511–1518 (2008).
   PubMed Web of Science ®Google Scholar